ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease

Phase 2

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: AGN-223575 ophthalmic solution
Drug: AGN-223575 vehicle ophthalmic solution

First Posted Date: 2015-05-06

Last Posted Date: 2019-04-05

Lead Sponsor: Allergan

Target Recruit Count: 236

Registration Number: NCT02435914

Locations: 🇺🇸
Eye Associates of Colorado Springs, Colorado Springs, Colorado, United States
🇺🇸
Eye Care Associates of Greater Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Whitsett Vision Group, Houston, Texas, United States

and more 25 locations

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

Phase 1

Completed

Conditions: Healthy Volunteers
Dry Eye Syndromes

Interventions: Drug: AGN-232411
Drug: AGN-232411 Vehicle

First Posted Date: 2015-04-20

Last Posted Date: 2016-07-14

Lead Sponsor: Allergan

Target Recruit Count: 77

Registration Number: NCT02420730

Locations: 🇺🇸
Montebello Medical Center, Inc., Montebello, California, United States
🇺🇸
Sall Research Center, Artesia, California, United States
🇺🇸
Lugene Eye Institute, Glendale, California, United States

Perception of Facial Expression in Subjects With and Without Crow's Feet Lines

Completed

Conditions: Healthy Volunteers

Interventions: Other: Photographic Review

First Posted Date: 2015-04-15

Last Posted Date: 2016-03-11

Lead Sponsor: Allergan

Target Recruit Count: 393

Registration Number: NCT02417077

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

Phase 2

Completed

Conditions: Painful Bladder Syndrome
Cystitis, Interstitial

Interventions: Combination Product: LiRIS®
Combination Product: LiRIS Placebo

First Posted Date: 2015-04-08

Last Posted Date: 2018-01-04

Lead Sponsor: Allergan

Target Recruit Count: 131

Registration Number: NCT02411110

Locations: 🇺🇸
Women's Health Specialty Care, Farmington, Connecticut, United States
🇺🇸
Regional Urology, LLC, Shreveport, Louisiana, United States
🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States

and more 31 locations

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

Phase 2

Completed

Conditions: Cystitis, Interstitial
Ulcer

Interventions: Drug: LiRIS®
Drug: LiRIS Placebo

First Posted Date: 2015-03-20

Last Posted Date: 2018-10-05

Lead Sponsor: Allergan

Target Recruit Count: 59

Registration Number: NCT02395042

Locations: 🇺🇸
Anne Arundel Urology, P.A., Annapolis, Maryland, United States
🇺🇸
Western New York Urology Associates, LLC, Cheektowaga, New York, United States
🇺🇸
Beaumont Health System, Royal Oak, Michigan, United States

and more 16 locations

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Phase 2

Completed

Conditions: Diabetes Mellitus
Diabetes Mellitus Complications
Gastroparesis

Interventions: Drug: Relamorelin
Drug: Placebo

First Posted Date: 2015-02-06

Last Posted Date: 2019-07-24

Lead Sponsor: Allergan

Target Recruit Count: 393

Registration Number: NCT02357420

Locations: 🇺🇸
Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸
River Birch Research Alliance LLC, Blue Ridge, Georgia, United States
🇺🇸
Gastroenterology Consultants, Virginia Beach, Virginia, United States

and more 87 locations

A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed

Conditions: Ocular Hypertension
Open-Angle Glaucoma

Interventions: Other: No Intervention

First Posted Date: 2015-01-28

Last Posted Date: 2015-09-21

Lead Sponsor: Allergan

Target Recruit Count: 150

Registration Number: NCT02348476

Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye

Not Applicable

Completed

Conditions: Dry Eye Syndromes

Interventions: Device: Intranasal Tear Neurostimulator

First Posted Date: 2014-12-10

Last Posted Date: 2020-01-31

Lead Sponsor: Allergan

Target Recruit Count: 21

Registration Number: NCT02313454

Locations: 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Refresh Optive® Gel Drops
Drug: REFRESH LIQUIGEL®

First Posted Date: 2014-10-31

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 188

Registration Number: NCT02280473

Locations: 🇺🇸
The Eye Center at Southern College of Optometry, Memphis, Tennessee, United States
🇺🇸
North Bay Eye Associates, Petaluma, California, United States
🇺🇸
Moyes Eye Center, PC, Kansas City, Missouri, United States

and more 7 locations

A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides

Phase 3

Completed

Conditions: Facial Rhytides
Glabellar Rhytides

Interventions: Drug: Normal Saline
Biological: OnabotulinumtoxinA

First Posted Date: 2014-10-10

Last Posted Date: 2017-07-25

Lead Sponsor: Allergan

Target Recruit Count: 787

Registration Number: NCT02261493

Locations: 🇬🇧
The Bosham Clinic, Chichester, United Kingdom
🇬🇧
The Gatehouse, Whitegate, United Kingdom
🇺🇸
Steve Yoelin, MD Medical Associates, Inc., Newport Beach, California, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy